Clinical Trial

A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 10, 2024 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study will evaluate the efficacy and safety of HS-10390 in subjects with primary IgA nephropathy, and explore the optimal dose for the treatment.
Trial Details
NCT Number NCT06635772
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Immunoglobulin a Nephropathy
Enrollment 90 participants
Start Date 2024-11
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2024-10-10